Goodwin attorneys advised AMAG Pharmaceuticals (AMAG) in its recently announced $700 million acquisition of Cord Blood Registry (CBR). The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2015.
Cord Blood Registry is the world’s largest stem cell collection and storage company serving pregnant women and their families. The company stores more than 600,000 cord blood and tissue units, which represents more than half of all privately stored cord units in the United States. Founded in 1992, CBR is dedicated to advancing the clinical application of newborn stem cells by partnering research institutions to establish FDA-regulated clinical trials. The company is based in California.
AMAG Pharmaceuticals is a high-growth specialty pharmaceutical company that uses its business and clinical expertise to bring medical therapies and other innovations to market that benefit and improve people’s lives. AMAG’s portfolio includes products in the areas of maternal health, anemia management and cancer supportive care. The company is traded on the Nasdaq exchange under ticker “AMAG” and is based in Massachusetts.
Earlier this year, Goodwin also advised AMAG on its $201 million common stock offering.
Additional information regarding AMAG’s acquisition of CBR is available in the press release.